The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma

Yasumasa Miyazaki, Takeo Kosaka, Shuji Mikami, Eiji Kikuchi, Nobuyuki Tanaka, Takahiro Maeda, Masaru Ishida, Akira Miyajima, Ken Nakagawa, Yasunori Okada, Yasufumi Sato, Mototsugu Oya

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC). Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes. Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1% and 72.8% in patients with VASH1 density (≥ 40/mm2) and 81.0% and 86.5% in their counterparts, respectively (P < 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion. Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC.

Original languageEnglish
Pages (from-to)4145-4153
Number of pages9
JournalClinical Cancer Research
Volume18
Issue number15
DOIs
Publication statusPublished - 2012 Aug 1

Fingerprint

Urinary Tract
Carcinoma
Microvessels
Neoplasms
Recurrence
Endothelial Cells
Survival
Research Design
Multivariate Analysis
Survival Rate
Biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. / Miyazaki, Yasumasa; Kosaka, Takeo; Mikami, Shuji; Kikuchi, Eiji; Tanaka, Nobuyuki; Maeda, Takahiro; Ishida, Masaru; Miyajima, Akira; Nakagawa, Ken; Okada, Yasunori; Sato, Yasufumi; Oya, Mototsugu.

In: Clinical Cancer Research, Vol. 18, No. 15, 01.08.2012, p. 4145-4153.

Research output: Contribution to journalArticle

Miyazaki, Yasumasa ; Kosaka, Takeo ; Mikami, Shuji ; Kikuchi, Eiji ; Tanaka, Nobuyuki ; Maeda, Takahiro ; Ishida, Masaru ; Miyajima, Akira ; Nakagawa, Ken ; Okada, Yasunori ; Sato, Yasufumi ; Oya, Mototsugu. / The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 15. pp. 4145-4153.
@article{a020b99d1ef749a9a2a9c0e51c19768b,
title = "The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma",
abstract = "Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC). Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes. Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1{\%} and 72.8{\%} in patients with VASH1 density (≥ 40/mm2) and 81.0{\%} and 86.5{\%} in their counterparts, respectively (P < 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion. Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC.",
author = "Yasumasa Miyazaki and Takeo Kosaka and Shuji Mikami and Eiji Kikuchi and Nobuyuki Tanaka and Takahiro Maeda and Masaru Ishida and Akira Miyajima and Ken Nakagawa and Yasunori Okada and Yasufumi Sato and Mototsugu Oya",
year = "2012",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-12-0073",
language = "English",
volume = "18",
pages = "4145--4153",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma

AU - Miyazaki, Yasumasa

AU - Kosaka, Takeo

AU - Mikami, Shuji

AU - Kikuchi, Eiji

AU - Tanaka, Nobuyuki

AU - Maeda, Takahiro

AU - Ishida, Masaru

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Okada, Yasunori

AU - Sato, Yasufumi

AU - Oya, Mototsugu

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC). Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes. Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1% and 72.8% in patients with VASH1 density (≥ 40/mm2) and 81.0% and 86.5% in their counterparts, respectively (P < 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion. Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC.

AB - Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC). Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes. Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1% and 72.8% in patients with VASH1 density (≥ 40/mm2) and 81.0% and 86.5% in their counterparts, respectively (P < 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion. Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC.

UR - http://www.scopus.com/inward/record.url?scp=84864442249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864442249&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-0073

DO - 10.1158/1078-0432.CCR-12-0073

M3 - Article

C2 - 22675166

AN - SCOPUS:84864442249

VL - 18

SP - 4145

EP - 4153

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -